Adequate relief in a treatment trial with IBS patients: A prospective assessment

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 912-919

  Passos, Maria C F ^a   Lembo, Anthony J ^a,f   Conboy, Lisa A ^b   Kaptchuk, Ted J ^b   Kelly, John M ^c,d   Quilty, Mary T ^b   Kerr, Catherine E ^b   Jacobson, Eric E ^b   Hu, Rong ^b   Friedlander, Elizabeth ^a   Drossman, Douglas A ^e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ENDICOTT COLLEGE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f University of North Carolina ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPERAMIDE; PLACEBO; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ACUPUNCTURE; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITAL ADMISSION; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHAM PROCEDURE; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ADOLESCENT; FOLLOW UP; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; YOUNG ADULT;

ACUPUNCTURE THERAPY; ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449137147     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.13     Document Type: Article

References (30)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
2. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005;3:717-25.
3. Drossman DA, Morris CB, Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005; 128:580-9.
4. Talley NJ. Irritable bowel syndrome. Intern Med J 2006;36:724-8.
5. Tack J, Fried M, Houghton LA et al. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspecti\ e. Aliment Pharmacol Ther 2006;24:183-205.
6. Mangel AW Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998;26:76-81.
7. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
8. Camilleri M, Northcutt AR, Kong S et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
9. Camilleri M, Chey WY Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
10. Miner PBJ, Pruitt RE, Carter F. Cilansetron is efficacious in treating diarrheal symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) over 3 months. Gastroenterology 2004;128:A29.
11. Bradette M, Moennikes H, Carter F et al. Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS-D): efficacy and safety in a 6 month global stud). Gastroenterology 2004;126:A42.
12. Coremans G, Clouse RE, Carter F et al. Cilansetron, a novel 5-HT3 antagonist demonstrated efficacy in males with irritable bowel syndrome with diarrhoea-predominance (IBS-D). Gastroenterology 2004;126:A643.
13. Kellow I, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to ealuate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6.
14. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119-26.
15. Tack J, Muller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13.
16. Mangel AW, Fehnel S. Adequate relief in lBS treatment trials: corrections to errors stated by Whitehead et al.. Am J Gastroenterol 2006;101:2884-5; author repl) 2885-7.
17. Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130: 1538-51.
18. Camilleri M, Mangel AW Fehnel SE et al. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40.
19. Whitehead WE, Palsson OS, Levy RE et al. Reports of "satisfactory relief" by lBS patients receiving usual medical care are confounded by baseline symptom severity and do not accuratel) reflect symptom improvement. Am J Gastroenterol 2006;101:1057-65.
20. Thompson WG. Irritable bowel syndrome: a management strategy. Baillieres Best Pract Res Clin Gastroenterol 1999;13:453-60.
21. Hammer J, Eslick GD, Howell SC et al. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-72.
22. Vanner SJ, Depew WT, Paterson WG et al. Predicthe alue of the Rome criteria for diagnosing the irritable bowel syndrome. Am I Gastroenterol 1999;94:2912-7.
23. Francis CY, Morris J, Whorwell PT. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
24. Patrick DL, Drossman DA, Frederick IO et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-11.
25. Costa PJ, McCrae RR. Psychological Assessment Resources. The NEO personality inventory manual. Psychological Assessment Resources Inc., Odessa, FL, 1985.
26. Beck AT, Ward CH, Mendelson M et al. An inventor) for measuring depression. Arch Gen Psychiatry 1961 ;4:561-71.
27. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom tmprovement in women witb diarrhea-irritable bowel syndrome. Am J Gastroenterol 2001;96: 2662-70.
28. Gordon 5, Ameen V. Bagby B et al. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment ethcacy. Dig Dis Sci 2003;48:1317-23.
29. Drossman DA, Patrick DL, Whitehead WE et al. Furtherx alidation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroen predominanterol 2000;95:999-1007.
30. Ameen g Heath AT, McSorley D et al. Global measure of adequate relief predicts clinically important difference in pain and is independent of baseline pain severity in irritable bowel syndrome. Gastroenterology 2007;132:A140.